GenSight Biologics Strengthens Regulatory Team with Two Key Hires
Event summary
- GenSight Biologics appointed Fang Li as Chief Regulatory Affairs & Quality Officer and Sabrina Chekroun as Senior Vice President, Regulatory Affairs and Quality.
- Fang Li brings over 30 years of experience in drug development, including senior regulatory roles at Opthea Ltd, Oculis SA, Graybug Vision, and Iveric Bio.
- Sabrina Chekroun has over 23 years of experience in international Regulatory Affairs, with leadership positions at Sanofi-Genzyme, AstraZeneca, Abivax, and Advicenne.
- The appointments follow recent regulatory milestones, including early access programs in France, Israel, and the United States.
The big picture
GenSight Biologics is bolstering its regulatory leadership as it prepares for a pivotal year marked by regulatory authorizations and the launch of a new global Phase III trial. The appointments of Fang Li and Sabrina Chekroun underscore the company’s focus on navigating complex regulatory landscapes in the US and Europe, critical for the success of its gene therapy candidates. The move reflects broader industry trends where regulatory expertise is increasingly vital for biopharma companies advancing innovative therapies.
What we're watching
- Regulatory Strategy
- How Fang Li and Sabrina Chekroun will shape GenSight’s global regulatory strategy amid planned Phase III trials and early access programs.
- Execution Risk
- Whether the new leadership can sustain the momentum of recent regulatory milestones in multiple markets.
- Market Dynamics
- The pace at which GenSight can advance its pipeline, particularly GS010 for Leber Hereditary Optic Neuropathy (LHON).
Related topics